Stock
Extremely heavy volume that accompanies a gap higher and a reversing candle after a lengthy uptrend is typically a sign of buyers’ exhaustion and...
Hi, what are you looking for?
Want to know where the stock market is headed next? In this week’s market update, Mary Ellen McGonagle analyzes key resistance levels and reveals...
Is a recession coming? In this video, Julius breaks down the latest updates to his powerful Sector Rotation Model, analyzing four key macroeconomic indicators...
When your investment portfolio isn’t gaining ground, it’s natural to feel uneasy, especially in a market that lacks direction. A headline-driven environment only adds...
Extremely heavy volume that accompanies a gap higher and a reversing candle after a lengthy uptrend is typically a sign of buyers’ exhaustion and...
The markets consolidated throughout the past week; the week was a shortened one with Monday, June 17th being a holiday on account of Bakri...
In this StockCharts TV video, Mary Ellen reviews the broader markets, takes a close look at NVDA and other year-to-date winners that sold off...
Last week, the broader market Indices hit another new high on Thursday before pulling back into Friday’s close. Not all areas participated, however, as...
Moving averages are a crucial charting tool, but many of us aren’t getting the most out of them. In this edition of StockCharts TV‘s...
In this edition of StockCharts TV‘s The Final Bar, Dave recaps a day where technology shares struggles, with leading names like NVDA and MU...
In this edition of StockCharts TV‘s The Final Bar, Dave answers viewer questions on using technical indicators on leveraged and inverse ETFs like SOXL...
Who would have thought a mid-week break would halt the stock market’s winning streak? Maybe the hot PMI reading leaked, or traders and investors...
Editor’s Note: This article was originally published on November 21, 2022.This article has absolutely nothing to do with trend following or the markets. I...
Gilead Sciences’ (GILD) new HIV prevention shot, lenacapavir, hit it out of the park in a late-stage trial, showing 100% effectiveness. 2,000 women participated...